WallStSmart

MiniMed Group, Inc. Common Stock (MMED)vsWaystar Holding Corp. Common Stock (WAY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

MiniMed Group, Inc. Common Stock generates 163% more annual revenue ($2.89B vs $1.10B). WAY leads profitability with a 10.2% profit margin vs -7.3%. WAY earns a higher WallStSmart Score of 51/100 (C-).

MMED

Hold

37

out of 100

Grade: F

Growth: 5.3Profit: 5.0Value: 5.0Quality: 5.0

WAY

Buy

51

out of 100

Grade: C-

Growth: 6.0Profit: 6.0Value: 5.7Quality: 6.0
Piotroski: 2/9Altman Z: 1.55
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for MMED.

WAYSignificantly Overvalued (-471.8%)

Margin of Safety

-471.8%

Fair Value

$4.15

Current Price

$24.07

$19.92 premium

UndervaluedFair: $4.15Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MMED1 strengths · Avg: 10.0/10
Operating MarginProfitability
136.0%10/10

Strong operational efficiency at 136.0%

WAY4 strengths · Avg: 9.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Operating MarginProfitability
23.6%8/10

Strong operational efficiency at 23.6%

Revenue GrowthGrowth
24.3%8/10

Revenue surging 24.3% year-over-year

Areas to Watch

MMED4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Free Cash FlowQuality
$-53.00M2/10

Negative free cash flow — burning cash

Profit MarginProfitability
-7.3%1/10

Currently unprofitable

WAY4 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.554/10

Distress zone — elevated risk

Return on EquityProfitability
3.2%3/10

ROE of 3.2% — below average capital efficiency

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
40.6x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : MMED

The strongest argument for MMED centers on Operating Margin. Revenue growth of 13.1% demonstrates continued momentum.

Bull Case : WAY

The strongest argument for WAY centers on Price/Book, Debt/Equity, Operating Margin. Revenue growth of 24.3% demonstrates continued momentum.

Bear Case : MMED

The primary concerns for MMED are EPS Growth, Return on Equity, Free Cash Flow.

Bear Case : WAY

The primary concerns for WAY are Altman Z-Score, Return on Equity, Piotroski F-Score. A P/E of 40.6x leaves little room for execution misses.

Key Dynamics to Monitor

MMED profiles as a turnaround stock while WAY is a growth play — different risk/reward profiles.

WAY is growing revenue faster at 24.3% — sustainability is the question.

WAY generates stronger free cash flow (57M), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

WAY scores higher overall (51/100 vs 37/100) and 24.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

MiniMed Group, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Minimed Group, Inc. is a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company is headquartered in Northridge, California.

Waystar Holding Corp. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Waystar Holding Corp. The company is headquartered in Lehi, Utah.

Visit Website →

Want to dig deeper into these stocks?